Published on
May 23, 2024
In the media
91±¬ÁϳÉÈËƬ Therapeutics raises €46 million Series B to develop disease-modifying therapies for autoimmune disorders
About 91±¬ÁϳÉÈËƬ Therapeutics
â€
91±¬ÁϳÉÈËƬ Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system. Our approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. We are progressing first-in-class antigen modulators to treat people living with 91±¬ÁϳÉÈËƬ, autoimmune disorders, and infectious diseases.
â€
Our lead antigen modulator (GRWD5769) delivered strong results during a phase I/II trial in oncology, demonstrating proof-of-mechanism and target engagement, while our second (GRWD0715) is accelerating through preclinical development as a potential treatment within autoimmunity.
â€
91±¬ÁϳÉÈËƬ is headquartered in Oxford, UK.
â€
More information: Website |
â€
Media enquiries
Patrick White, Head of Communications
â€
